Overview

A fully integrated biopharmaceutical company with a robust pipeline across multiple therapeutic areas.

Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

11/15/21	Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer REDWOOD CITY, Calif. and SHANGHAI, China , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has
11/10/21	Coherus BioSciences Announces New Employment Inducement Grants REDWOOD CITY, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Nov. 5, 2021 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 177,500 shares of
11/08/21	Coherus BioSciences Reports Third Quarter 2021 Results – Key milestones achieved driving near-term commercial product portfolio expansion – – Three BLAs now under FDA review: PD-1 inhibitor toripalimab, biosimilar Lucentis®, biosimilar Humira® – – Multiple additional applications to FDA expected in 2022 – – UDENYCA® delivers 3rd quarter 2021 net sales
11/05/21	Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 REDWOOD CITY, Calif. , Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end

View All